作者: Shin-Seok Yang , Na-Ri Kim , Kwang-Bo Park , Young-Soo Do , Kyounghwan Roh
DOI: 10.15283/IJSC.2013.6.1.37
关键词:
摘要: Background and Objectives Half of patients with critical limb ischemia (CLI) are ineligible for revascularization at diagnosis. The aim this study was to assess the safety feasibility intramuscular human umbilical cord blood-derived mesenchymal stem cell (hUCB-MSC) therapy in CLI due atherosclerosis obliterans (ASO) or thromboangiitis (TAO).